Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Pathologic dural invasion is associated with regional recurrence in olfactory neuroblastoma: A multi‐institutional study
Tang, Anthony , Fung, Nicholas , Champagne, Pierre‐Olivier , Fernandez‐Miranda, Juan C. , Gardner, Paul , Hwang, Peter H. , Nayak, Jayakar V. , Patel, Chirag , Patel, Zara M. , Celda, María Peris, Sanusi, Olabisi , Thorp, Brian D. , Zenonos, Georgios A. , Zwagerman, Nathan T. , Nayak, Jayakar V , Patel, Zara , Pinheiro-Neto, Carlos, Snyderman, Carl H , Wang, Eric W , Choby, Garret , Hwang, Peter H , Taori, Suchet , Fung, Nicholas, Almeida, João Paulo , Pinheiro‐Neto, Carlos , Gompel, Jamie J. Van , Geltzeiler, Mathew , Choby, Garret

Mayo Clinic

International Forum of Allergy & Rhinology | November 13, 2024 | Volume: 15 | Issue: 4 | Pages: 373-383

10.1002/alr.23489 | PMID 39535364 Get It

AbstractObjectiveNeck metastases are a poor prognostic factor in olfactory neuroblastoma (ONB). Pathologic dural invasion (pathDI) may increase the risk of neck metastases due to invasion of dural lymphatics. We aim to evaluate the prognostic value of pathDI in predicting rates of neck metastases and recurrence using a large, multicenter database of ONB patients.Data sourcesRetrospective review of a prospective, multicenter database of electronic health records of all patients who presented with ONB between 2005 and 2021 at nine tertiary academic care centers within North America.Review methodsClinicopathologic features including modified Kadish staging systems, margin status, treatment modalities, Hyams grading, follow‐up time, and survival.ResultsOf 258 ONB patients, 189 patients met the inclusion criteria. The 10‐year neck recurrence‐free survival (neck‐RFS) rates were 85.7% (75.6‒97.3) and 61.8% (47.9‒79.8) for patients without and with pathDI, respectively (p = 0.018). Time‐to‐event multivariable regression analysis found pathDI to have an odds ratios of 9.7 (95% confidence interval [CI] 1.2–80.4, p = 0.04) for neck‐RFS and 9.5 for RFS at any site (95% CI 1.1–83.3, p = 0.04).ConclusionIn multivariable analysis, the presence of pathDI appears to be the strongest predictor of neck recurrence and recurrence at any site. Future studies exploring the benefit of elective neck dissection or radiation for patients with pathDI may impact disease management.
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024
Thompson, John A. , Schneider, Bryan J. , Brahmer, Julie R. , Zaid, Mohammad Abu , Achufusi, Amaka, Armand, Philippe , Bermas, Bonnie L. , Braaten, Tawnie , Chokshi, Saurin , Crees, Zachary , Davies, Marianne, Deng, Changchun , Gesthalter, Yaron , Jallouk, Andrew , Khalil, Maya, Marr, Alissa , McGettigan, Suzanne , Medina, Theresa , Mohindra, Nisha , Patel, Sandip Pravin , Prosek, Jason, Reddy, Sunil , Reid, Pankti , Ryder, Mabel , Shofer, Scott , Sosman, Jeffrey A. , Zucker, Stephen D. , Lyons, Megan , Hang, Lisa, Ryder, Mabel , Berkenstock, Meghan , Bermas, Bonnie , Budde, Lihua E. , Jain, Michael D. , Jain, Prantesh , Kaffenberger, B , Lechner, Melissa G , Li, Tianhong , McPherson, Jordan P. , Medina, Theresa Michelle , Olszanski, Anthony J. , Oluwole, Olalekan O. , Ryan, John, Salman, Huda , Santomasso, Bianca , Wang, Yinghong , Zaha, Vlad G , Awotiwon, Ajibola

Mayo Clinic

Journal of the National Comprehensive Cancer Network | November 13, 2024 | Volume: 22 | Issue: 9 | Pages: 582-592

10.6004/jnccn.2024.0057 | PMID 39536465 Get It

The NCCN Guidelines for the Management of Immunotherapy-Related Toxicities are intended to provide oncology practitioners with guidance on how to manage the wide-ranging and potentially fatal toxicities that may occur with cancer immunotherapy. The guidelines address immune-related adverse events related to immune checkpoint inhibitors, CAR T-cell therapies, and lymphocyte engagers (which include T-cell–engaging bispecific antibodies). These NCCN Guidelines Insights highlight recent guideline updates pertaining to the management of emerging toxicities related to cancer immunotherapy.
Large‐scale deep proteomic analysis in Alzheimer's disease brain regions across race and ethnicity
Fox, Edward J., Liu, Yue , Dammer, Eric B. , Modeste, Erica , Duong, Duc M. , Yin, Luming, Trautwig, Adam N., Guo, Qi , Xu, Kaiming , Ping, Lingyan, Reddy, Joseph S. , Allen, Mariet , Quicksall, Zachary , Heath, Laura , Scanlan, Jo, Wang, Minghui , Linden, Abby Vander , Poehlman, William L. , Chen, Xianfeng , Baheti, Saurabh , Ho, Charlotte C.G. , Nguyen, Thuy , Yepez, Geovanna, Mitchell, Adriana O., Oatman, Stephanie R., Wang, Xue , Carrasquillo, Minerva M. , Runnels, Alexi , Golde, Todd E. , Zhang, Bin , Haroutunian, V., Gearing, Marla , Lah, James J., Jager, Philip L. De , Bennett, David A., Ertekin‐Taner, Nilüfer , Wingo, Aliza P. , Wingo, Thomas S. , Seyfried, Nicholas T. , Bennett, David A. , Bennett, David A. , Ho, Charlotte, Dammer, Eric B , Wingo, Thomas S , Seifar, Fatemeh , Shantaraman, Anantharaman , Ping, Lingyan, Wang, Erming , Carrasquillo, Minerva M. , Beach, Thomas, Serrano, Geidy E. , Dickson, Dennis W. , Lee, Edward B. , Prokop, Stefan , Barnes, Lisa L. , Greenwood, Anna, Levey, Allan I.

Mayo Clinic

Alzheimer's & Dementia | November 13, 2024 | Volume: 20 | Issue: 12 | Pages: 8878-8897

10.1002/alz.14360 | PMID 39535480 Get It

Abstract INTRODUCTION Alzheimer's disease (AD) is the most prevalent neurodegenerative disease, yet our comprehension predominantly relies on studies within non‐Hispanic White (NHW) populations. Here we provide an extensive survey of the proteomic landscape of AD across diverse racial/ethnic groups. METHODS Two cortical regions, from multiple centers, were harmonized by uniform neuropathological diagnosis. Among 998 unique donors, 273 donors self‐identified as African American, 229 as Latino American, and 434 as NHW. RESULTS While amyloid precursor protein and the microtubule‐associated protein tau demonstrated higher abundance in AD brains, no significant race‐related differences were observed. Further proteome‐wide and focused analyses (specific amyloid beta [Aβ] species and the tau domains) supported the absence of racial differences in these AD pathologies within the brain proteome. DISCUSSION Our findings indicate that the racial differences in AD risk and clinical presentation are not underpinned by dramatically divergent patterns in the brain proteome, suggesting that other determinants account for these clinical disparities. Highlights We present a large‐scale proteome (∼10,000 proteins) of DLPFC (998) and STG (244) across AD cases. About 50% of samples were from racially and ethnically diverse brain donors. Key AD proteins (amyloid and tau) correlated with CERAD and Braak stages. No significant race‐related differences in amyloid and tau protein levels were observed in AD brains. AD‐associated protein changes showed a strong correlation between the brain proteomes of African American and White individuals. This dataset advances understanding of ethnoracial‐specific AD pathways and potential therapies.
Recent Developments in Glioblastoma‐On‐A‐Chip for Advanced Drug Screening Applications
Maity, Surjendu , Bhuyan, Tamanna , Kawakita, Satoru , Sharma, Saurabh , Nguyen, Huu Tuan , Najafabadi, Alireza Hassani , Chen, Junjie , Yilgor, Can , Choroomi, Auveen, Torres, Emily, Mecwan, Marvin , Wang, Zhaohui , Quiñones‐Hinojosa, Alfredo , Jucaud, Vadim , Dokmeci, Mehmet R. , Kawakita, Satoru , Sharma, Saurabh , Nguyen, Huu Tuan , Hassani Najafabadi, Alireza , Khorsandi, Danial , Yilgor, Can , Moniz-Garcia, Diogo, Jucaud, Vadim , Dokmeci, Mehmet Remzi , Khademhosseini, Ali , Jewell, Christopher M. , Ermis, Menekşe , Falcone, Natashya , Mandal, Kalpana , Torres, Emily, John, Johnson V. , Akbari, Mohsen , Moniz‐Garcia, Diogo , Khademhosseini, Ali

Mayo Clinic

Small | November 13, 2024 | Volume: 21 | Issue: 1 | Pages: No page available

10.1002/smll.202405511 | PMID 39535474 Get It

Abstract Glioblastoma (GBM) is an aggressive form of cancer, comprising ≈80% of malignant brain tumors. However, there are no effective treatments for GBM due to its heterogeneity and the presence of the blood‐brain barrier (BBB), which restricts the delivery of therapeutics to the brain. Despite in vitro models contributing to the understanding of GBM, conventional 2D models oversimplify the complex tumor microenvironment. Organ‐on‐a‐chip (OoC) models have emerged as promising platforms that recapitulate human tissue physiology, enabling disease modeling, drug screening, and personalized medicine. There is a sudden increase in GBM‐on‐a‐chip models that can significantly advance the knowledge of GBM etiology and revolutionize drug development by reducing animal testing and enhancing translation to the clinic. In this review, an overview of GBM‐on‐a‐chip models and their applications is reported for drug screening and discussed current challenges and potential future directions for GBM‐on‐a‐chip models.
The Global Prevalence of Iron Deficiency in Collegiate Athletes: A Systematic Review and Meta‐Analysis
Thompson, Christineil , Block, Darci R , Foster, Nathan R. , Steien, Dana, Galardy, Paul J. , Al‐Huniti, Ahmad , Block, Darci, Galardy, Paul J , Wang, Zhen , Hassett, Leslie C.

Mayo Clinic

Pediatric Blood & Cancer | November 12, 2024 | Volume: 72 | Issue: 2 | Pages: No page available

10.1002/pbc.31415 | PMID 39530537 Get It

ABSTRACTAthletes are at high risk of iron deficiency even without anemia. In this systematic review and meta‐analysis that included 17,519 athletes in 122 references from 23 countries, participating in 62 unique sports over a 41‐year timeframe, approximately 53.9% of student‐athletes were found to be hypoferritinemic (ferritin concentration below 50 mcg/L) with 23.0% percent showing absolute iron deficiency based on current definitions (ferritin concentration below 20 mcg/L). These findings strongly suggest that changes in clinical practice guidelines are warranted to enable routine screening for iron deficiency among adolescent and collegiate athletes.
Iron Deficiency in Collegiate Athletes Obtaining Preparticipation Hemoglobinopathy Screening in the Upper Midwest
Thompson, Christineil , Fairweather, DeLisa , Block, Darci R , Foster, Nathan R. , Steien, Dana, Galardy, Paul J. , Al‐Huniti, Ahmad , Block, Darci, Galardy, Paul J , Fairweather, DeLisa , Trushina, Eugenia , Wang, Zhen

Mayo Clinic

Pediatric Blood & Cancer | November 12, 2024 | Volume: 72 | Issue: 2 | Pages: No page available

10.1002/pbc.31437 | PMID 39529284 Get It

ABSTRACTObjectiveIron and other biologically important metals are essential to mitochondrial function but are not routinely evaluated. Their equilibrium is critical to the optimal performance of cells with high metabolic activity such as neurons, cardiomyocytes, and skeletal myocytes. Teenagers are at a high risk of iron deficiency even without anemia. Metal ion imbalances can cause cognitive impairments, muscle weakness, and sudden cardiac death. We aim to assess the current prevalence of iron deficiency among collegiate athletes in the Upper Midwest.MethodsOur study is a multicenter, retrospective chart review of outpatient clinics in a regional healthcare system between January 2012 and December 2023, and a national public database between 2017 and March 2020. We reviewed the ferritin concentrations of regional collegiate athletes having preparticipation sport evaluations and nationally in the NHANES database.ResultsWe identified 643 unique individuals aged 16–21 years with 253 having ferritin screening. Iron deficiency (ferritin <20 mcg/L) was present in 24.5% and hypoferritinemia (ferritin <50 mcg/L) was present in 66.7% of collegiate athletes. From the NHANES database, 12.7% of active sampled participants aged 16–21 years were iron deficient.ConclusionOur study findings suggest the need for universal screening for iron deficiency among collegiate athletes given the high prevalence of iron deficiency in both the retrospective chart review and NHANES database analysis. Given the critical role of metal ion homeostasis to optimal mitochondrial function, these findings may warrant the inclusion of ferritin testing in cardiac, neurological, and skeletal muscle evaluations.
TMIC-41. RBBP4/P300 COMPLEX CONTROLS GENES MODULATING ANGIOGENESIS AND IMMUNOSUPPRESSION IN GLIOBLASTOMA MICROENVIRONMENT
Mapunda, Josephine, Htee, Hser, Mortazavifarsani, Seyedehsahar, Suzuki, Yuta , Kitange, Gaspar J. , Wang, Li , Verma, Vivek , Hoeppner, Luke H. , Sarkaria, Jann N.

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii307-viii307

10.1093/neuonc/noae165.1219 Get It

Abstract The RBBP4/p300 complex was recently shown to control genes critical for DNA damage repair and may play a role in glioblastoma (GBM) therapy responsiveness, especially to temozolomide (TMZ). However, the role of this complex in the modulation of the GBM tumor microenvironment (GBM-TME) remains elusive. Because pro-tumorigenic GBM-TME is primarily due to angiogenesis and immune tolerance, we evaluated whether the RBBP4/p300 complex may control these critical processes. To that end, we used shRNA to silence each RBBP4/p300 complex member in GBM43 cells and RNAseq to identify angiogenesis and immune genes regulated by this complex. Our data demonstrated that silencing RBBP4 or p300 suppressed the expression of HIF1α and several other hypoxia response genes, including VEGFA and DDIT4, suggesting that RBBP4/p300 complex may regulate angiogenesis. Consistent with a role in regulating angiogenesis, culture medium conditioned by GBM43 cells expressing the control non-targeting shRNA (shNT) significantly induced angiogenic tube formation by human umbilical vein endothelial cells (HUVEC). In contrast, this effect was blocked by the medium conditioned by the shRBBP4 or shp300 expressing cells. Both shRBBP4 and shp300 expressing cells failed to activate HIF1α accumulation and other signaling in response to hypoxia. Additionally, the control shNT-conditioned medium inhibited IFN-γ production while the medium conditioned by the shRBBP4 or shp300 expressing cells supported IFN-ɣ production from CD8+ T cells. Intriguingly, silencing RBBP4 or p300 also suppressed the expression of CCL2 and PD-L1 (CD274). CCL2 protein is a chemokine that promotes TME infiltration by myeloid-derived suppressor cells (MDSCs), while PD-L1 interacts with PD1 to suppress cytotoxic CD8+ T cell activation. Although this is an ongoing investigation, we conclude that RBBP4/p300 complex mediates the expression of hypoxia response genes, including HIF1α, and immunosuppressive genes, including PD-L1, and this activity may enhance angiogenic and immunosuppressed GBM-TME, making this complex a potential target for GBM therapy.
IMMU-49. TARGETING ALTERNATIVE SPLICING VARIANTS TO STIMULATE ANTI-TUMOR IMMUNITY IN A NOVEL SYNGENEIC MOUSE MODEL OF DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT
Owens, Geoffrey C., Kim, Wi-Jin, Armellini, Amber, Na, Brian , Nathanson, David A. , Xing, Yi , Wang, Anthony , Pan, Yang , Sun, Matthew Z. , Peeters, Sophie , Treger, Janet M. , Lee, Alex , Everson, Richard G. , Daniels, David J. , Liau, Linda M. , Prins, Robert M.

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii163-viii164

10.1093/neuonc/noae165.0642 Get It

Abstract The prognosis for pediatric high-grade gliomas associated with mutations in the H3-A3 histone gene is very poor. To investigate whether peptide-pulsed dendritic cells (DC) together with checkpoint blockade might be a potential treatment modality for diffuse hemispheric glioma, H3 G34-mutant (DHG), we have developed a novel mouse model, and utilized a novel bioinformatics pipeline to identify tumor-associated peptide antigens (TAs). We used the RCAS/tv-A system to target the expression of H3/G34R and PDGFb, and to knock out p53 in neural progenitors in transgenic C57BL/6 neonatal mice. Three independent cell lines were obtained that expressed transcripts associated with oligodendrocyte and interneuron lineages, and formed lethal tumors after intracranial implantation. To identify TAs, we implemented a new computational workflow to identify nonapeptides generated from alternative splicing of mRNAs that were highly enriched in the tumor transcriptomes of two DHG patients, and predicted to bind the HLA-A*2:01 class I allele carried by these patients. Three of the candidate peptides were conserved in the mouse and also predicted to bind the H2-Kb MHC I allele carried by C57/BL6 mice. Using our syngeneic mouse model, we showed that DCs pulsed with these peptides together with anti-PD1 mAb provided a significant survival benefit compared with checkpoint inhibitor and DCs pulsed with peptides that were not predicted to bind the H2-Kb allele. Splenocytes isolated from successfully treated mice were analyzed through bulk TCR sequencing, and in comparison with control mice and publicly-accessible TCR libraries, 6 highly-represented TCR clonotypes were identified only in treated mice. In summary, we demonstrate that effective TAs can be extracted from RNAseq data, and can be targeted with DC vaccination to generate a systemic anti-tumor cytotoxic T cell response to eliminate DHG in a novel immunocompetent mouse model.
IMMU-25. B-CELL BASED THERAPY (BVAX) PRODUCES ANTIBODIES TO SUPPRESS GLIOBLASTOMA TUMOR MIGRATION AND INVASION
Katz, Joshua , Cervantes, Gustavo Ignacio Vázquez , Olson, Ian , Hou, David , Dapash, Mark , Wan, Hanxiao, Rashidi, Aida , Arjmandi, Tarlan, Shaikh, Zainab H, Jones, Grace, Zhang, Peng , Heimberger, Amy B. , Riviere-Cazaux, Cécile , Miska, Jason , Fischietti, Mariafausta, Castro, Brandyn , Wang, Si , Arrieta, Victor Andrés , Najem, Hinda , Jones, Grace, Platanias, Leonidas C. , McCortney, Kathleen , Horbinski, Craig , Stupp, Roger , Ahmed, Atique U. , Sonabend, Adam M , Heimberger, Amy B. , Lesniak, Maciej S. , Burns, Terry C. , Fischietti, Mariafausta , Lee-Chang, Catalina

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii157-viii158

10.1093/neuonc/noae165.0618 Get It

Abstract Glioblastoma (GBM) presents as a highly aggressive and malignant brain tumor with limited treatment options. Despite the availability of existing therapies, the invasive characteristics of GBM frequently result in tumor recurrence and poor prognosis. We previously developed a B-cell-based therapy (BVax) that has shown promising results in its ability to induce therapeutic responses in preclinical models of GBM. Our research revealed potency of BVax can be attributed to its robust antigen-presenting capability, cognate antigen specificity with T cells, and ability to generate tumor-reactive antibodies. The present study aims to characterize the unique antigenic reactivity of BVax-derived antibodies by evaluating their immunological effects and therapeutic potential in both murine models and GBM patient-specific samples. Leveraging CD45.1 and CD45.2 congenic mouse models, we first revealed that BVax preferentially migrated to glioma-bearing brains upon intravenous injection, resulting in a CD38+CD20-CD19+ plasmablast phenotype. To further characterize the reactivity of BVax-derived immunoglobulins (Ig), we utilized proteomic analysis and identified preferential targets of Gelsolin, Fibronectin, Versican, Fibrinogen, and collagen type IV alpha, commonly associated with cell motility and the extracellular matrix. Microdialysis data confirmed the increased presence of many of these BVax-derived Igs-recognized antigens in tumor regions compared to normal brain regions in GBM patients. Utilizing purified BVax-derived antibodies from patient specimen, in vitro cell motility assays demonstrated a significant prevention of the invasion and migration of cell lines from patient derived xenograft (PDX). In this study, we concluded that BVax elicits antitumor activity through targeted migration to tumor-bearing regions, differentiation into plasmablasts, and robust secretion of specific Igs that retain the ability to inhibit functionalities associated with cell invasion and migration. Here, we present the first in-depth study that characterizes GBM patients’ antibody reactivity, specifically a subset of inflammatory B cells (BVax) with therapeutic effects that offer an indication for a new direction of immunotherapies.
The Feasibility and Usability of an Artificial Intelligence-Enabled Conversational Agent in Virtual Reality for Patients with Alcohol-Associated Cirrhosis: A Multi-Methods Study
Clark, Allistair , Mehra, Muskaan , Danovitch, Itai , Yang, Ju Dong , Vipani, Aarshi , Wang, Yun F. , Ayoub, Walid S. , Trivedi, Hirsh D. , Wu, Tiffany , Shah, Vijay H. , Liran, Omer , Clark, Allistair , Mehra, Muskaan , Spiegel, Brennan , Wu, Tiffany , Yeo, Yee Hui , Osilla, Karen Chan , Yang, Ju Dong , Kuo, Alexander , Kim, Hyunseok , Samaan, Jamil S. , Spiegel, Brennan

Mayo Clinic

Journal of Medical Extended Reality | November 11, 2024 | Volume: 1 | Issue: 1 | Pages: 257-270

10.1089/jmxr.2024.0033 | PMID 42558099 Get It